|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ƥ��,��Ӧ�ԽӴ��� |
|
ϸ�������� |
| ��������������� | |
|
��� |
|
�µ��� |
|
��ѧ�� |
| PubMed | |
|
Article by ��� |
|
Article by �µ��� |
|
Article by ��ѧ�� |
��Ӧ�ԽӴ���Ƥ����ϸ�����ӵı��
���1, �µ���1, ��ѧ��2
1. ͬ�ô�ѧҽѧԺ����ͬ��ҽԺƤ����, �Ϻ�200180;
2. �Ϻ���Ƥ�����Բ�ҽԺ
��Ӧ�ԽӴ���Ƥ���dz����ijٷ��ͱ�̬��Ӧ��Ƥ����,ϸ�����ӵı���ڸò��ķ�������������Ҫ���á�����������������-�������-1����Ҫ�ڱ�Ӧ�ԽӴ���Ƥ���յ������δ�ʹ�ʸ�˹ϸ����ֲ��ܰͽ�ľۼ��Ϳ�ԭ�����,������-�úͰ���-4�DZ�Ӧ�ԽӴ���Ƥ��ЧӦ����Ҫ��һ�Ծ���������õ�ϸ������,��������һЩϸ�������ڱ�Ӧ�ԽӴ���Ƥ���������á�����ϸ�����ӹ�ͬӰ���Ӧ�ԽӴ���Ƥ�ķ�������չ��ת�顣
1. ͬ�ô�ѧҽѧԺ����ͬ��ҽԺƤ����, �Ϻ�200180;
2. �Ϻ���Ƥ�����Բ�ҽԺ
1. ͬ�ô�ѧҽѧԺ����ͬ��ҽԺƤ����, �Ϻ�200180;
2. �Ϻ���Ƥ�����Բ�ҽԺ
[2] Cumberbetch M, Dearman RJ, Kimber I. Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology, 1997,92:388-395.
[3] Okazaki F, Kanzaki H, Fujii K, et al. Initial recruitment of interferon-gamma-producing CD8 + effector cells, followed by infiltration of CD4 + cells in 2,4,6-trinitro-1-chlorobenzene (TNCB)-induced murine contact hypersensitivity reactions. J Dermatol, 2002, 29:699.
[4] Dearman RJ, Cumberbatch M, Hilton J, et al. A re-appraisal of the skin-sensitizing activity of 2,4-dinitrothiocyanobenzene. Food Chem Toxicol, 1997, 35:261-269.
[5] Biedermann T, Mailhammer R, Mai A,et al. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur J Immunol, 2001, 31:1582-1591.
[6] Garrigue JL, Nicolas JF, Fraginals R, et al. Optimization of the mouse ear swelling test for in vivo and in vitro studies of weak contact sensitizers. Contact Dermatitis, 1994, 30:231-237.
[7] Westphal GA, Schnuch A, Moessner R, et al. Cytokine gene polymorphisms in allergic contact dermatitis. Contact Dermatitis, 2003,48:93-98.
[8] Groves RW, Allen MH, Ross EL, et al. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol, 1995, 132:345-352.
[9] Sheu MY, Fowler AJ, Kao J, et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol, 2002, 118:94-101.
[10] Pichowski JS, Cumberbatch M, Dearman, et al. Investigation of induced changes in interleukin 1 beta mRNA expression by cultured human dendritic cells as an in vitro approach to skin sensitization testing. Toxicol In Vitro, 2000, 14:351-360.
[11] Nishimura N, Tohyama C, Satoh M, et al. Defective immune response and severe skin damage following UVB irradiation in interleukin-6-deficient mice. Immunology, 1999, 97:77-83.
[12] Wang B, Zhuang L, Fujisawa H, et al. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J Immunol, 1999,162:277-283.
[13] Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity, 2002, 17:375-387.
[14] Yawalkar N, Brand CU, Braathen LR. Interleukin-12 expression in human afferent lymph derived from the induction phase of allergic contact dermatitis. Br J Dermatol, 1998, 138:297-300.
[15] Albanesi C, Scarponi C, Cavani A, et al. Interleukin-17 is produced by both Thl and Th2 lymphocytes, and modulates interferongamma-and interleukin-4-induced activation of human keratinocytes.J Invest Dermatol, 2000, 115:81-87.
[16] Meng X, Sawamura D, Tamai K,et al. Keratinocyte gene therapy for systemic diseases. Circulating interleukin 10 released from gene-transferred keratinocytes inhibits contact hypersensitivity at distant areas of the skin. J Clin Invest, 1998, 101:1462-1467.